Most Favored Nation pricing and Affordability of GLP-1RAs for Obesity Treatment in MedicareMost Favored Nation pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare
This economic evaluation examines the 10-year US pricing and affordability for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity treatment in Medicare. This economic evaluation examines the 10-year US pricing and affordability for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity treatment in Medicare.
Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 YearsBreast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 Years
This cross-sectional study investigates patterns of recommended screening for breast, cervical, and colorectal cancer in US women aged 45 to 64 years.
Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study findsEndoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds
A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity. A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral Read More
GLP-1s and Hepatic Events; ‘Shame, Taboo, Hygiene’; Treating Late-Onset IBDGLP-1s and Hepatic Events; ‘Shame, Taboo, Hygiene’; Treating Late-Onset IBD
(MedPage Today) — Among U.S. adults with diabetes and steatotic liver disease in the All of Us cohort, new use of a GLP-1 receptor agonist was linked with a 38% to 42% lower risk of hepatic events over nearly 3 years of median follow-up. (American… (MedPage Today) — Among U.S. adults with diabetes and Read More
Semaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trialSemaglutide cuts BMI by 19% in treatment-resistant young adults with severe obesity, finds trial
A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at the European Congress on Obesity (ECO26) in Read More
De-Escalated Treatment for Early Breast Cancer Continues to Gain MomentumDe-Escalated Treatment for Early Breast Cancer Continues to Gain Momentum
(MedPage Today) — The number of women skipping sentinel lymph node biopsy (SLNB) for early breast cancer doubled over a 5-year period to become the predominant strategy for low-risk disease, a prospective study showed.
The proportion of patients…
Cancer fatigue may ease within weeks as common stimulant shows benefitCancer fatigue may ease within weeks as common stimulant shows benefit
A new meta-analysis in Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief for cancer-related fatigue.
Semaglutide may improve motivation with major depressive disorderSemaglutide may improve motivation with major depressive disorder
Treatment with semaglutide significantly improves measures of motivation in patients with major depressive disorder (MDD), according to a study published April 29 in JAMA Psychiatry. Treatment with semaglutide significantly improves measures of motivation in patients with major depressive disorder (MDD), according to a study published April 29 in JAMA Psychiatry.
GLP-1 Drug Linked to Cases of Rare Vision-Altering ConditionGLP-1 Drug Linked to Cases of Rare Vision-Altering Condition
(MedPage Today) — Two patients taking the GLP-1 receptor agonist dulaglutide (Trulicity) developed choroidal lymphoid hyperplasia (CLH), a rare, benign condition of the uveal tract, that resolved after the patients stopped the drug. In both cases… (MedPage Today) — Two patients taking the GLP-1 receptor agonist dulaglutide (Trulicity) developed choroidal lymphoid hyperplasia (CLH), a Read More
Breast cancer cells with doubled genomes may dodge immunotherapy by turning off key immune signalsBreast cancer cells with doubled genomes may dodge immunotherapy by turning off key immune signals
An epigenetic mechanism by which tumors manage to hide from the body’s immune defenses has just been described by an international scientific team led by the University of Liège and the Dana-Farber Cancer Institute. These findings open up avenues for new therapeutic strategies combining epigenetics and immunotherapy. The paper is published in the journal Cancer Cell.